

Bibliography

1. Górriz JL, Soler MJ, Navarro-González JF, et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. *J Clin Med*. 2020;9(4):947.
2. Gentilella R, Pechtnr V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? *Diabetes Metab Res Rev*. 2019;35(1):e3070.
3. Dungan K, DeSantis A. Glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. UpToDate. Last updated Sep 1, 2021. Accessed October 12, 2021. Available at: https://www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus?search=glp%201%20agonist&source=search_result&selectedTitle=2~98&usage_type=default&display_rank=1.
4. Frias JP, Wynne AG, Matyjasek-Matuszek B, et al. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. *Diabetes Obes Metab*. 2019;21(9):2048-57.
5. Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. *Ther Adv Endocrinol Metab*. 2021;12:1-15
6. Jain AB, Ali A, Gorgojo Martínez JJ, et al. Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. *Int J Clin Pract*. 2021; 75(2):e13731.
7. Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: Rationale and practical guidance. *Clin Diabetes*. 2020;38(4):390-402.
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2021